Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-15T08:55:08.187Z Has data issue: false hasContentIssue false

Etomidate Vaping: An Emerging Substance Use Pattern in Singapore - A Case Series

Published online by Cambridge University Press:  31 July 2026

C. Q. Low*
Affiliation:
Institute of Mental Health, Singapore, Singapore
A. Yiyang
Affiliation:
Institute of Mental Health, Singapore, Singapore
K. Gomathinayagam
Affiliation:
Institute of Mental Health, Singapore, Singapore
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Introduction

The emergence of etomidate vaping represents a novel form of substance misuse, particularly concerning in Singapore’s strict regulatory environment. Etomidate is a short-acting intravenous hypnotic agent used in anaesthesia, but recent reports from Hong Kong and Mainland China describe recreational misuse via vaping devices. Singapore has reported over 70 cases of etomidate-laced e-vaporisers investigated or prosecuted locally, with several associated fatalities.

Objectives

To describe the first documented cases of etomidate vaping in Singapore, examining clinical presentations, treatment approaches, and outcomes to raise awareness among healthcare providers and inform public health responses.

Methods

We present two cases of etomidate vaping encountered at the Institute of Mental Health, Singapore’s tertiary psychiatric hospital, between October 2024 and August 2025. Cases were selected based on self-reported use of etomidate-containing vaping products and availability of comprehensive clinical documentation. Clinical information was extracted from electronic medical records, including demographic details, substance use patterns, clinical presentations, treatment interventions, and follow-up outcomes.

Results

Two cases were identified: one male (age 33) and one female (age 26). Both presented with distinctive clinical features including trance-like states and behavioural disturbances. The male patient showed sustained remission following structured inpatient treatment, while the female patient initially maintained abstinence but later experienced relapse precipitated by occupational stress. Notably, withdrawal symptoms were absent during initial cessation but emerged with repeated use patterns in the female patient, suggesting evolving dependence potential. Both cases demonstrated rapid functional impairment and significant financial expenditure within short timeframes.

Conclusions

Etomidate vaping represents an emerging public health threat requiring immediate healthcare system adaptation, including enhanced screening protocols, specialised laboratory testing capabilities, and modified treatment approaches. The contrasting outcomes between inpatient and outpatient management highlight the need for intensive engagement strategies, whilst the evolution of withdrawal symptoms with repeated use suggests increasing dependence potential over time.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.